Related Experiment Video
Updated: Oct 6, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
Pharmacists improve diabetes outcomes: a randomized controlled trial
Journal of the American Pharmacists Association : Japha
|January 14, 2022
Summary
Adding pharmacists to healthcare teams significantly improves diabetes management and patient satisfaction. This approach enhances glucose control and adherence to preventive care, addressing primary care physician shortages.
Area of Science:
- Health Services Research
- Clinical Pharmacy
- Diabetes Management
Background:
- Growing shortage of primary care physicians necessitates innovative healthcare delivery models.
- Interdisciplinary teams are being explored as part of healthcare reform to address access issues.
- Pharmacists are increasingly recognized for their potential role in expanding healthcare services.
Purpose of the Study:
- To evaluate the impact of integrating a pharmacist into an interprofessional health team on diabetes outcomes.
- To determine if pharmacist involvement improves glycemic control (HbA1c) in diabetic patients.
- To assess secondary outcomes including medication therapy problems, preventive care adherence, and patient satisfaction.
Main Methods:
- A 2-phase pilot study involving Medicaid-eligible patients with diabetes.
- Randomization to either standard care (control) or standard care plus pharmacist care (intervention).
- Primary outcome: change in glycated hemoglobin (A1c); Secondary outcomes: medication therapy problems, preventive care adherence, healthcare utilization, and patient satisfaction.
Main Results:
- Intervention group showed a significantly greater reduction in A1c compared to the control group (0.91 pp difference, P=0.0218).
- Pharmacists identified 2638 medication therapy problems and improved adherence to preventive care visits (nutrition, ophthalmology, dentistry).
- Patient satisfaction was markedly higher in the intervention group, with 78% rating their experience as excellent versus 37% in the control group.
Conclusions:
- Pharmacist comanagement of diabetes patients leads to significant improvements in glucose control and patient satisfaction.
- Integrating pharmacists into interprofessional teams is an effective strategy to enhance diabetes care.
- This model demonstrates the value of pharmacists in addressing healthcare needs and improving patient outcomes.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
430
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
430
Dipeptidyl Peptidase 4 Inhibitors
280
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
280
Oral Hypoglycemic Agents: Biguanides and Glitazones
332
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
332
Oral Hypoglycemic Agents: Glinides
291
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
291
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
306
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
306
Glucagon-like Receptor Agonists
462
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
462

